Company patents
Prognosys Biosciences, Inc.
Prognosys Biosciences, Inc. surprisingly maintains a laser focus on Genetic & Microbiological Assays, representing 100.0% of its portfolio, despite a significant 92.9% decline in patenting activity in this area so far in 2026. While also heavily invested in Laboratory Apparatus (86.7% of portfolio) and Material & Chemical Analysis (82.2%), the company shows a notable shift away from Peptides & Proteins, which saw a 100.0% year-over-year decline in 2025.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
45 US filings (since 2023) · 4 categories · 5 themes
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Self-contained or modular devices designed to automate and integrate multiple steps of molecular diagnostic assays, from sample preparation to result interpretation, often for point-of-care or high-throughput applications.
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Patents
Showing 1-10 of 105